Gastroenterology

Gastroenterology

Volume 136, Issue 4, April 2009, Pages 1157-1160
Gastroenterology

Editorial
PPARG: A New Independent Marker for Colorectal Cancer Survival

https://doi.org/10.1053/j.gastro.2009.02.022Get rights and content

References (32)

  • G.D. Girnun et al.

    Synergy between PPARgamma ligands and platinum-based drugs in cancer

    Cancer Cell

    (2007)
  • A.C. Society

    Cancer facts and figures

    (2008)
  • E.E. Calle et al.

    Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms

    Nat Rev Cancer

    (2004)
  • E.E. Calle et al.

    Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults

    N Engl J Med

    (2003)
  • B.M. Forman et al.

    Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta

    Proc Natl Acad Sci U S A

    (1997)
  • S.A. Kliewer et al.

    Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma

    Proc Natl Acad Sci U S A

    (1997)
  • Cited by (9)

    • Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells

      2016, Journal of Steroid Biochemistry and Molecular Biology
      Citation Excerpt :

      By contrast, our previous studies show elevated AKR1C3 deprives AML cells of J-series prostaglandins that can act as endogenous PPAR ligands. Given that PPARg ligands have been investigated for the treatment of various cancer types for example neuroblastomas [60], colorectal [61], breast and prostate cancers [62,63]. It was hypothesized that the role in CaP for AKR1C3 may be to silence PPAR signaling.

    View all citing articles on Scopus

    Conflicts of interest The authors disclose no conflicts.

    View full text